Biotech leader John Maraganore has had a respected career in the industry, having built Alnylam Pharmaceuticals over 19 years into the leading RNAi therapeutics company in the world with five marketed RNAi medicines. He reflected on some of the current issues facing the biotech sector at the BIO CEO & Investor meeting in New York on 11 February – including the challenging economic climate, political changes in the US and competition from China.
Reflections From Biotech Leader John Maraganore
The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.
More from Leadership
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.